Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Cas13 shines a light on SARS-CoV-2 variants

Cas13 shines a light on SARS-CoV-2 variants

Now, a new study published on the medRxiv* preprint server describes and benchmarks SHINEv2, a Cas13-based nucleic acid diagnostic for SARS-CoV-2 detection. SHINEv2 combines temperature sample processing and lyophilized reagents to simplify the test procedure and assay distribution immensely.

4 Nov 2021

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

A comprehensive characterization of the immune responses between SARS-CoV-2 infected individuals with wildtype (WT) and Δ382 SARS-CoV-2.

3 Nov 2021

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Humoral immunity following heterologous and homologous COVID-19 vaccination regimens

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies.

3 Nov 2021

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

Antibody response of COVID-19 patients to SARS-CoV-2 and seasonal coronaviruses

Scientists conducted a cohort study and measured the prevalence and the levels of antibody responses to the nucleocapsid protein of SARS-CoV-2 and four seasonal human coronaviruses.

3 Nov 2021

BNT162b2 mRNA COVID-19 vaccine effectiveness amongst Italian healthcare workers

BNT162b2 mRNA COVID-19 vaccine effectiveness amongst Italian healthcare workers

A new study has been published in Vaccines that evaluated the effectiveness of Cominarty against documented SARS-CoV-2 infection and symptomatic diseases in the medium to long term.

1 Nov 2021

Structural and molecular contributions to understanding antibody recognition of pathogenic viruses

Structural and molecular contributions to understanding antibody recognition of pathogenic viruses

A new review discusses how molecular and structural biology have contributed to our understanding of antibody recognition of HIV-1, SARS-CoV-2, and Zika.

1 Nov 2021

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

A new study develops an inhaled microfluidic microsphere with a genetically engineered membrane from the ACE2 receptor-overexpressing cells and macrophages.

1 Nov 2021

SARS-CoV-2 incidence and mortality in US school opening model

SARS-CoV-2 incidence and mortality in US school opening model

Researchers reported regional variations on the impact of school reopening policy on the community rate of SARS-CoV-2 infection.

29 Oct 2021

Causal effect of school closures on reducing COVID-19 spread in Japan

Causal effect of school closures on reducing COVID-19 spread in Japan

A new study estimated the causal effect of school closures on reducing the spread of COVID-19.

29 Oct 2021

Japanese study on SARS-CoV-2 breakthrough infections

Japanese study on SARS-CoV-2 breakthrough infections

Researchers evaluated SARS-CoV-2 incidence in Japan regarding the timing of the vaccination program and surge in COVID-19 cases among the staff of a large referral hospital in Tokyo. This study is posted to the medRxiv* preprint server.

28 Oct 2021

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.